Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem Sells 7,250 Shares

Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem sold 7,250 shares of Edwards Lifesciences stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $85.80, for a total value of $622,050.00. Following the transaction, the chief financial officer now directly owns 19,074 shares in the company, valued at approximately $1,636,549.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Edwards Lifesciences Stock Down 1.5 %

EW opened at $84.68 on Wednesday. The business has a 50 day moving average price of $90.23 and a 200 day moving average price of $79.16. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The firm has a market cap of $50.97 billion, a P/E ratio of 36.50, a price-to-earnings-growth ratio of 4.28 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Research analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Edwards Lifesciences by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 52,363,400 shares of the medical research company’s stock worth $3,992,709,000 after buying an additional 729,984 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Edwards Lifesciences by 9.5% during the first quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock worth $1,813,089,000 after buying an additional 1,644,869 shares during the last quarter. Brown Advisory Inc. lifted its holdings in shares of Edwards Lifesciences by 20.1% during the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after buying an additional 3,048,274 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Edwards Lifesciences by 2.4% during the fourth quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock worth $1,283,098,000 after buying an additional 393,109 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth approximately $648,540,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EW has been the topic of several research analyst reports. Morgan Stanley lifted their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. Royal Bank of Canada lifted their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Evercore ISI reduced their price target on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a report on Friday, April 26th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Finally, Citigroup lifted their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $92.71.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.